MDZ: Yale-New Haven Hospital

New Haven, Connecticut 06504

0 studies enrolling now · 1 studies all time

What they study most

ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC

Studies at this site

• A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations — Completed